The U.S. Department of Justice and the DEA issued a final order on April 23, 2026, moving FDA-approved cannabis drug products and state-licensed medical cannabis to Schedule III of the Controlled Substances Act - the most concrete shift in federal cannabis policy since the CSA was enacted in 1970. The order took effect April 28, upon publication in the Federal Register. For medical cannabis operators, the immediate and most tangible consequence is relief from Section 280E of the Internal Revenue Code. For adult-use operators, almost nothing changes.
What the Order Actually Does - and Doesn't Do
The order covers two categories of cannabis. First, any drug product containing cannabis that has received FDA approval - currently Epidiolex, Marinol, Syndros, and Cesamet. Second, and far more consequential for the broader industry, all cannabis subject to a state-issued license to manufacture, distribute, or dispense cannabis for medical purposes. Forty states currently have such licensing regimes in place.
The DOJ issued the order under Section 811(d)(1) of the CSA, a treaty-power provision that allows the Attorney General to reschedule substances to fulfill U.S. obligations under the 1961 Single Convention on Narcotic Drugs. That pathway let DOJ bypass the standard notice-and-comment rulemaking process entirely and act immediately. It's a legally aggressive move - and opponents are already preparing to challenge it.
Here's what the order does not do: it does not legalize cannabis federally. It does not decriminalize possession. It does not expunge prior convictions. It does not dissolve the Bank Secrecy Act's anti-money-laundering requirements, and the SAFE Banking Act remains unpassed. Recreational cannabis - every adult-use license in California, Colorado, Michigan, and every other state - stays Schedule I.
To put it plainly: the federal government has drawn a line between medical and recreational cannabis, and that line now carries real financial and regulatory weight.
280E Relief Is Real, but Registration Is Required
Since 1982, Section 280E has barred businesses trafficking in Schedule I or II controlled substances from deducting ordinary and necessary business expenses. For state-licensed cannabis companies, that has meant paying federal income tax on gross profit rather than net income - an effective tax rate that has crushed margins across the industry, particularly for vertically integrated operators carrying the overhead of cultivation, processing, and retail under one roof.
Schedule III status eliminates that burden for medical cannabis operators beginning in tax year 2026. The Treasury and IRS also announced on April 23 that they plan to issue guidance on retrospective 280E relief for prior tax years - an acknowledgment, remarkable in itself, that rescheduling will have "significant positive tax consequences" for the medical cannabis sector. What that guidance will actually look like, and how broadly it will apply, remains to be seen.
The catch is that Schedule III status for state-licensed medical operators is not automatic. Operators must register with the DEA. The registration portal opened April 29. The application covers seven sections: business and ownership information, state license details, criminal and licensure history, and a compliance section requiring detailed disclosure of operating procedures - ordering and storage protocols, theft reporting, security measures. The annual registration fee is $794.
Operators who file within 60 days of the Federal Register publication date - by June 27, 2026 - may continue operating under their state licenses while applications are pending. Several leading multistate operators, including Trulieve, Green Thumb Industries, and Glass House Brands, had already filed as of early May.
For smaller single-state operators, the administrative lift is manageable but not trivial. Operators who have maintained rigorous compliance documentation under state seed-to-sale tracking requirements will find that most of the DEA's disclosure requirements map reasonably well onto existing records. Those running leaner compliance operations may need to do some work before filing.
The Two-Track Structure and What Comes Next for Adult-Use
Alongside the order, the DOJ published a notice of proposed rulemaking initiating a separate, expedited administrative hearing process to consider rescheduling all cannabis - including recreational cannabis - from Schedule I to Schedule III. This is a fresh proceeding. The prior Biden Administration rulemaking, which drew over 43,000 public comments and stalled in early 2025 amid procedural disputes, has been formally withdrawn.
The new hearing timeline is compressed: notices of intention to participate are due May 24; the DEA will select participants by June 22; the hearing itself is set to begin June 29 and conclude no later than July 15, 2026. If the process holds - and litigation could disrupt it - a final rule covering all cannabis could arrive by late 2026.
What's striking here is the fork this creates. If the rulemaking concludes with all cannabis moved to Schedule III, the medical-recreational distinction embedded in the current order becomes moot. If it doesn't - or if litigation delays or partially invalidates the rulemaking outcome - the federal government will have formalized a two-tier cannabis framework that could persist for years. Adult-use operators would remain Schedule I businesses, still locked out of standard business expense deductions, still navigating the same banking constraints, still carrying the full weight of federal prohibition on their books.
Smart Approaches to Marijuana has already announced plans to sue over the treaty-power mechanism DOJ used to bypass notice-and-comment rulemaking, retaining former Attorney General Bill Barr to lead that effort. The order's severability clause - designed to keep remaining provisions intact if a court strikes part of the order - signals that DOJ anticipated exactly this and tried to build in some structural resilience. Whether that holds under APA scrutiny is an open question.
The Immediate Business Calculus for Operators
For licensed medical cannabis operators, the registration deadline is the first operational priority. Miss the June 27 window and the path to continued operations under federal Schedule III compliance becomes considerably more complicated. The $794 annual fee is not the burden; the compliance documentation is the thing to start assembling now.
For multistate operators with both medical and adult-use licenses, the accounting and tax treatment is about to get more complex, not less. Medical operations may qualify for 280E relief while adult-use operations do not - which means clean separation of revenue, cost of goods sold, and operating expenses by license type is no longer just a compliance preference, it's a financial necessity.
For the payments and banking sector, the order changes almost nothing in the short term. Cannabis businesses - medical or recreational - still operate under the Bank Secrecy Act's anti-money-laundering framework. Financial institutions considering whether to extend services to cannabis clients will watch the litigation and the rulemaking outcome before moving. The structural barriers to standard banking access remain.
The broader implication for the industry is this: the federal government has, for the first time, affirmatively recognized state medical cannabis licensing regimes as the vehicle for federally compliant cannabis commerce. That is a meaningful shift in the legal architecture, even if it leaves most of the industry's day-to-day compliance obligations exactly where they were. Adult-use operators, in particular, should be paying close attention to the June 29 hearing - because that proceeding is the only near-term mechanism through which their federal status could change.
